Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free NAVB Stock Alerts

Navidea Biopharmaceuticals (NAVB) Competitors

Navidea Biopharmaceuticals logo
Compare

NAVB vs. CARM, SCPS, ARDS, TRVN, and AMPE

Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Carisma Therapeutics (CARM), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Trevena (TRVN), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry.

How does Navidea Biopharmaceuticals compare to Carisma Therapeutics?

Navidea Biopharmaceuticals (NYSE:NAVB) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Carisma Therapeutics -254.28%N/A -192.17%

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 199,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Navidea Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Navidea Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Carisma Therapeutics Neutral

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Carisma Therapeutics beats Navidea Biopharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Navidea Biopharmaceuticals (NYSE:NAVB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Scopus BioPharma N/A N/A N/A

Scopus BioPharma has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Scopus BioPharma Neutral

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500.

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Aridis Pharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 49.48, meaning that its stock price is 4,848% more volatile than the S&P 500.

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Trevena?

Navidea Biopharmaceuticals (NYSE:NAVB) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Trevena Neutral

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Trevena$443K0.02-$40.29M-$47.04N/A

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Trevena N/A N/A -119.55%

Summary

Navidea Biopharmaceuticals beats Trevena on 5 of the 8 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Navidea Biopharmaceuticals Neutral

Ampio Pharmaceuticals has a beta of 7.65, indicating that its stock price is 665% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ampio Pharmaceuticals has higher earnings, but lower revenue than Navidea Biopharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Ampio Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAVB vs. The Competition

Export
MetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE Exchange
Market Cap$10K$321K$6.25B$22.95B
Dividend YieldN/AN/A2.73%4.03%
P/E Ratio0.00N/A29.0428.58
Price / SalesN/A0.08476.6123.57
Price / CashN/AN/A27.6219.03
Price / BookN/AN/A9.674.68
Net Income-$15.18M-$6.86M$3.55B$1.07B

Navidea Biopharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
CARM
Carisma Therapeutics
2.3313 of 5 stars		$0.00
-16.7%		$1.00
+199,900.0%		N/A$21K$10.77M0.0020
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/A0.0030
TRVN
Trevena
N/A$0.01
flat		N/AN/A$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NAVB) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel